Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A

Trial Profile

Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs GSK 1437173A (Primary)
  • Indications Herpes zoster
  • Focus Registrational; Therapeutic Use
  • Acronyms ZOSTER-002
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 29 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 25 Feb 2016 Planned number of patients changed from 1847 to 1846, according to ClinicalTrials.gov record.
    • 19 Feb 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top